ALGN Align Technology
Category creator with durable professional lock-in, but growth is stuck and competition real
The business
Align Technology invented the clear aligner category and dominates it via Invisalign, sold on a per-case submission model to orthodontists and dentists globally. Its iTero intraoral scanner creates a digital workflow that integrates with Invisalign treatment planning. Revenue is case-volume driven with modest hardware/software recurring streams layered on top.
Quality gate · 86/100
Moat & management
| Moat | narrow moat |
| Source | switching costs |
| Trajectory | stable |
| Management | adequate |
The durable economic engine is the professional B2B2C lock-in: orthodontists who invest in iTero scanners, complete tiered Invisalign certification programs, and build their practice workflows around Align's ecosystem face real costs to switch. Consumer brand pull reinforces this — patients ask for Invisalign by name. However, core founding patents have expired, enabling competition at every price point, and Chinese domestic players are aggressively taking share in the most important growth market; 67.6% gross margins confirm the premium-end moat holds, but the moat is not widening.
Capital allocation discipline is solid — net cash balance sheet, consistent 2.6% annual buyback cadence, and 1.22x FCF conversion signal owner-oriented behavior. However, revenue compounding at only 2.6% over five years in a still-underpenetrated global market points to strategic execution gaps, particularly in China and international pricing.
Owner-earnings inputs
| Owner earnings (TTM) | 576.79M |
| Owner-earnings yield | 4.5% |
| Free-cash-flow yield | 4.6% |
| Growth used (normalized) | 7.0% |
| Market-implied growth (reverse DCF) | 9.8% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 11.9% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 617.16M | 7.0% | 551.57M |
| 2 | 657.62M | 6.6% | 525.27M |
| 3 | 697.81M | 6.1% | 498.13M |
| 4 | 737.35M | 5.7% | 470.42M |
| 5 | 775.86M | 5.2% | 442.38M |
| 6 | 812.93M | 4.8% | 414.26M |
| 7 | 848.15M | 4.3% | 386.27M |
| 8 | 881.14M | 3.9% | 358.65M |
| 9 | 911.49M | 3.4% | 331.57M |
| 10 | 938.83M | 3.0% | 305.22M |
Key risks
- Chinese domestic competitors (subsidized, government-favored) structurally capping the highest-growth international segment
- Low-end commoditization compressing blended ASPs as the category matures beyond early adopters
- Revenue growth remaining structurally low (~3%) rather than reverting toward historical double-digits
Catalysts
- China market stabilization and re-acceleration as geopolitical friction eases or local strategy adapts
- AI-enhanced treatment planning (complex adult cases, GP channel expansion) unlocking a new volume tier at premium ASPs
Recent news
score · 8 articles
- ALGN or SAUHY: Which Is the Better Value Stock Right Now?
- Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year?
- Is Align Technology Stock Underperforming the Dow?
- Align Technology (ALGN) Just Overtook the 50-Day Moving Average
- Q1 Earnings Outperformers: Align Technology (NASDAQ:ALGN) And The Rest Of The Dental Equipment & Technology Stocks
- A Look At Align Technology (ALGN) Valuation As Market Signals Send Mixed Messages
- Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure
- Align Technology Pitches AI-Powered Digital Dentistry Platform Beyond Invisalign
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF